The article 'Thrombelastography Today: Practicability and Analytical Power' by Hänecke and Klouche [1] is interesting in the respect that it warns users to follow strict rules and avoid errors to ensure result quality. The article however requires some comments from the system manufacturer side: Hänecke and Klouche are not consistent about instrument name and test nomenclature. In 2003, due to the registration of the trademark TEG ® by a US-based company, Pentapharm took the decision to differentiate its largely shock insensitive method from the pendulumbased, shock-sensitive, earlier thrombelastographic methods. The Pentapharm method was then renamed to thromboelatometry, the instrument name changed to ROTEM ® and all test names to XXTEM (e.g. INTEM). All reagents were trademarked xx-TEM ® (e.g. in-TEM ® ). To avoid problems with the rights owner of the TEG trademark, authors should respect the trademark and not use 'TEG' in connection with the Pentapharm product. Pentapharm welcomes the scientific approach for evaluation of the ROTEM ® system with the emphasis on general operation conditions and site specifications in a laboratory environment. Pentapharm would however have wished this to happen using a more recent instrument model following Pentapharm instructions for use. Pentapharm GmbH started refining the original instrument in 2002 with ROTEG 05; in 2004 the ROTEM ® Gamma and in 2007 the ROTEM ® delta as state of the art models were introduced. The authors did all their experiments using a 1999 ROTEG 04 model by the original inventor of the system. Most of their points of critic have been known for a long time and have been addressed and solved since Pentapharm started refining the original instrument.
The article 'Thrombelastography Today: Practicability and Analytical Power' by Hänecke and Klouche [1] is interesting in the respect that it warns users to follow strict rules and avoid errors to ensure result quality. The article however requires some comments from the system manufacturer side: Hänecke and Klouche are not consistent about instrument name and test nomenclature. In 2003, due to the registration of the trademark TEG ® by a US-based company, Pentapharm took the decision to differentiate its largely shock insensitive method from the pendulumbased, shock-sensitive, earlier thrombelastographic methods. The Pentapharm method was then renamed to thromboelatometry, the instrument name changed to ROTEM ® and all test names to XXTEM (e.g. INTEM). All reagents were trademarked xx-TEM ® (e.g. in-TEM ® ). To avoid problems with the rights owner of the TEG trademark, authors should respect the trademark and not use 'TEG' in connection with the Pentapharm product. Pentapharm welcomes the scientific approach for evaluation of the ROTEM ® system with the emphasis on general operation conditions and site specifications in a laboratory environment. Pentapharm would however have wished this to happen using a more recent instrument model following Pentapharm instructions for use. Pentapharm GmbH started refining the original instrument in 2002 with ROTEG 05; in 2004 the ROTEM ® Gamma and in 2007 the ROTEM ® delta as state of the art models were introduced. The authors did all their experiments using a 1999 ROTEG 04 model by the original inventor of the system. Most of their points of critic have been known for a long time and have been addressed and solved since Pentapharm started refining the original instrument.
Practicability of Rotational Thrombelastography
In table 1, the authors show the influence of the ambient temperature fluctuation on the test results (especially on temperatures lower than a standard room temperature of 21 °C). Many instruments must be operated in defined environmental conditions to ensure consistent results. Pentapharm discourages use of the system near an open window or an air conditioning outlet (user manual chapter 3.2). Furthermore users are advised to warm blood samples for approximately 10 min at 37 °C (e.g. in the sample pre-warming station of ROTEM ® Gamma or ROTEM ® delta) if the instrument is not used at the point of care (POC) and the sample cannot be tested immediately after sampling (user manual chapter 6.2.2). In table 5, the precision of the automated pipette is tested at different volume settings: 10 μl, 20 μl and 300 μl; the results are found unsatisfactory. The minimum volume used in ROTEM ® pipetting is 20 μl. Precision testing for 10 μl is therefore not necessary. Since 2002, all Pentapharm made instruments are delivered with a calibrated and certified eLine pipette. Regulations concerning calibration oblige laboratories to check calibration of their pipettes in regular intervals. The user manual states the procedure and indicates acceptable errors of the pipette at various volumes (e.g. 1.0% at 20 μl). It also indicates that pipettes out of these ranges need to be sent to the manufacturer for maintenance and recalibration (ISO 8655). A new quality certificate will be supplied upon each calibration for the user's documentation (user manual chapter 14.10). Hänecke and Klouche [1] state that extremely prolonged coagulation times in patients with coagulation disorders abrogate the potential saving of time. We, as many POC users, question this argument. ROTEM ® is mainly used for detection of bleeding tendency and/or the case thereof in a perioperative setting. At a POC setting, the graphical result develop-ment can be monitored dynamically. Any delay in clot formation in a patient sample can be interpreted as 'impaired coagulation'. The combination of 4 of the 5 ROTEM ® tests (INTEM, EXTEM, FIBTEM, APTEM, HEPTEM) can lead to rapid targeted treatment [2] [3] [4] [5] . Typical long clotting times (CT) are seen in heparinized patients using the intrinsic activator (INTEM). CT can be used to judge heparinization. To detect underlying pathologies, HEPTEM containing heparinase (or to some extent EXTEM) may be used. EXTEM-based ROTEM ® tests also contain a heparin-neutralizing agent. Thus, the combination of e.g. an EXTEM and an INTEM test may be used to confirm or rule out accidental heparin administration. Direct evaluation of the patient's coagulation status with ROTEM ® at the POC is considered very rapid as compared to the return of laboratory results by many authors [4, [6] [7] [8] [9] [10] .
Principle of Rotational Thrombelastography
Hänecke and Klouche [1] state that heparin and other drugs affect results. This is also true for many other tests in the clinical laboratory, and not a problem per se. It is always necessary to know possible limitations of a test. Respective warnings can be found in the instrument operator manual and the reagent insert sheets. Moreover, the heparin interference in certain tests is used to judge heparinization, and the protamin interference can be used to discriminate residual heparin effect from protamin overdosage [11] . Hänecke and Klouche [1] also warn for the unknown hemostatic potential of transfused blood products and their influence on the fibrinolytic system. They advise to take great care to interpret whole blood thromboelastography data from patients receiving transfusions. There we cannot agree. Today most authors agree that thromboelastometry is an excellent tool to monitor the effect of transfusions or of the component substitution therapy with blood components [2, 3, 12] . As thromboelastometry and thromboelastography visually show fulminant fibrinolysis, it is actually an excellent method to monitor the hemostatic state of hyperfibrinolytic patients after receiving treatment [4, 13] .
Analytical Power of Rotational Thrombelastography
Hänecke and Klouche [1] claim that it is not possible to validate ROTEM ® tests because it is impossible to provide a description of the incorrectness of the system for the following reasons: i) there is no standardized control material available, ii) there is no defined reference method, iii) there is no definition of the target values to be expected. However: i) Two levels of standardized controls are available from Pentapharm: ROTROL N and ROTROL P. These control materials are plasma-based. Whole blood cannot be stabilized as a control material. This situation is not much different from blood gas analysis where even more artificial control material is accepted for the same reason: a whole blood control cannot be produced. ii) In coagulation, definition of a reference method is generally much more difficult than in clinical chemistry, due to the complex processes measured. Even for tests as 'old' as prothrombin time and activated partial thromboplastin time, reference methods are still debated or not available. As thromboelastometric tests rely on whole blood, again the preparation of an international standard -the usual procedure in cases where a true reference method is not feasible -is not possible. Work towards standardization is ongoing. ROTEM ® and the older, pendulum-based thrombelastographic methods correlate well [14, 15] . Correlation studies between e.g. ROTEM ® FIBTEM MCF and Clauss fibrinogen are also available [10, 15] . iii) Reference ranges for each of the ROTEM ® tests have been established in a multicentric study [16] . Tentative guidelines for trauma patients, heart surgery, liver transplant, and others have been published recently or publication is under way [2, 3, [17] [18] [19] .
Quality Assessment
When assessing the performance of the system (table 3 As sample type, the authors used not only the recommended citrated whole blood (user manual chapter 6.2) but also freshly prepared plasma. The obtained precision data for citrated whole blood were close to the ranges published by Pentapharm, despite the non-Pentapharm reagents. For the freshly prepared plasma CVs obtained were high and particularly elevated for the clot formation time and the maximum clot firmness. This may be due to artifacts because of partial activation of the few remaining platelets during plasma preparation. As fresh plasma preparations are difficult to handle for thromboelastometry, Pentapharm does not recommend plasma as sample material! The plasma based ROTROL N and ROTROL P control materials supplied by Pentapharm do however give reproducible results. There, the platelets are completely inactivated during the lyophilization process and the remaining fibrin clot is very reproducible. platelets/μl the FIBTEM amplitude may be false high and that the fib-TEM reagent (containing Ca 2+ and cytochalasin D) may have failed to block all the platelets. This appears plausible and may require further evaluation. As very high platelet count in combination with bleeding is very rare in the operating room, few reports are available on this phenomenon. With platelet counts in the normal range, the fib-TEM reagent is able to block the available platelets. Pentapharm has received reports from patients with higher platelet counts where the fib-TEM reagent had no difficulty completely inhibiting platelet counts of approximately 650,000/μl (personal communication Dr. DiFlorio, Napels, Italy). Recently a study of this effect has been initiated by Pentapharm. We completely agree with the authors that patient treatment should never be based on single test results but as many results as available together with the patient history. In addition, the clinical picture should be considered at all times for rational and targeted treatment.
